with a flow-rate of 1.0 mL/min. Analysis wavelength was set at 290 nm. Column chromatography was carried out with Merck silica gel 60-120, 230-400 mesh, and RP-C18. TLC was run on Merck aluminium pre-coated silica gel 60 F 254 and RP C-18
plates. All the chemicals were purchased from Merck India Ltd.
Isolation procedure of 1-4
The n-hexane extract (8 g) was chromatographed on a silica gel column (5.0×45 cm; 60-120 mesh, 150 g; Merck), eluting with a gradient of n-hexane-EtOAc (1:0 → 0:1, each 1 L) to give ten fractions (A1-A10). Fr. A3 (1.5 g) was subjected to silica gel CC (3.0×50 cm; 60-120 mesh, 50 g; Merck) with n-hexane-EtOAc (9.5:0.5 → 9:1, each 0.5 L) resulting in the isolation of 4 (50.1 mg). The CHCl 3 extract (30 g) was applied to silica gel CC (5.0×70 cm; 230-400 mesh, 800 g; Merck) eluting with a 100% CHCl 3 to give eight fractions (B1-B8). The separation of fraction B2 (550 mg) by silica gel CC (3.0×50 cm; 230-400 mesh, 17 g; Merck) eluted with isocratic nhexane:EtOAc (3:2, each 500 mL) yielded fractions B2-1-B2-7. Fr. B2-1 (230 mg) was further subjected to reverse phase C-18 CC (1.5×50 cm; 40-63 µm, 23 g; Merck) using a gradient of MeOH:H 2 O (1:3 → 1:1, each 500 mL) to afford 1 (61.9 mg). The separation of subfraction B3 (1.91 g) over silica gel column (4.0×60 cm; 230-400 mesh, 60 g; Merck) eluting with isocratic n-hexane:EtOAc (3:7, each 500 mL) to give fractions B3-2-B3-8. Fraction B3-2 (350 mg) was further purified by reverse phase C-18 CC (1.5×50 cm; 40-63 µm, 30 g; Merck) using MeOH:H 2 O (1:5 → 1:1, each 500 mL) to give compound 2 (57.5 mg). The fraction B8 (250 mg) was chromatographed over reverse phase C-18 column (1.5×50 cm; 40-63 µm, 25 g; Merck) using MeOH:H 2 O (0.5:9.5 → 1:1, each 500 mL) to afford 3 (30.6mg).
Atlantolone (3) 
